Evidence map›Paper›PMID 36934250›Full record

ReviewTrials2023

What do we talk about when we talk about "equipoise"? Stakeholder interviews assessing the use of equipoise in clinical research ethics.

Brian Dewar, Stephanie Chevrier, Julie De Meulemeester, Mark Fedyk, Rosendo Rodriguez, Simon Kitto, Raphael Saginur, Michel Shamy

Full text readReview
In one paragraph

Review in Trials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Brian DewarOttawa Hospital Research Institute, Ottawa, Canada.ORCID http://orcid.org/0000-0002-9222-5420
Stephanie ChevrierOttawa Hospital Research Institute, Ottawa, Canada.
Julie De MeulemeesterOttawa Hospital Research Institute, Ottawa, Canada.
Mark FedykUniversity of California, Davis, Davis, USA.
Rosendo RodriguezDepartment of Medicine, University of Ottawa, Ottawa, Canada.
Simon KittoDepartment of Innovation in Medical Education, University of Ottawa, Ottawa, Canada.
Raphael SaginurOttawa Hospital Research Institute, Ottawa, Canada.
Michel ShamyOttawa Hospital Research Institute, Ottawa, Canada. mshamy@toh.ca.

Funding

CIHR 201702EPP
6 · The paper itself

Abstract

introductionEquipoise, generally defined as uncertainty about the relative effects of the treatments being compared in a trial, is frequently referenced as an ethical standard for the conduct of randomized clinical trials. However, it seems to be defined in several different ways and may be used differently by different individuals. We explored how clinical researchers, chairs of research ethics boards, and philosophers of science define and reason with this term.

methodsWe completed semi-structured interviews about clinical trial ethics with 15 clinical researchers, 15 research ethics board chairs, and 15 philosophers of science/bioethicists. Each participant was asked a standardized set of 10 questions, 4 of which were specifically about equipoise. All interviews were conducted telephonically and transcribed. Responses were grouped and analysed via a modified grounded theory method.

resultsForty-three respondents defined equipoise in 7 logically distinct ways, and 2 respondents could not explicitly define it. The most common definition, offered by 14 respondents (31%), defined "equipoise" as a disagreement at the level of a community of physicians. There was significant variability in definitions offered between and within groups. When asked how they would "operationalize" equipoise - i.e. check or test for its presence - respondents provided 7 alternatives, the most common being in relation to a literature review (15/45, 33%). The vast majority of respondents (35/45, 78%) felt the concept was helpful, though many acknowledged that the lack of a clear definition or operationalization was problematic.

conclusionThere is significant variation in definitions of equipoise offered by respondents, suggesting that parties within groups and between groups may be referring to different concepts when they reference "equipoise". This non-uniformity may impact fairness and transparency and opens the door to potential ethical problems in the evaluation of clinical trials - for instance, a patient may understand equipoise very differently than the researchers enrolling her in a trial, which could cause her agreement to participate to be based upon false premises.

Indexed as

Ethics, ResearchPhysiciansEthics, ClinicalFemaleHumansRandomized Controlled Trials as TopicResearch DesignTherapeutic EquipoiseUncertaintyClinical trialsEquipoiseEthicsResearch

Identifiers

PMID36934250
PMCPMC10024829

What OpenQuestion holds

Textfull text, public
LicenceCC BY
measurements read44
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.